

The investor brief

Completed formulations.

A focused route to agricultural markets.

NONTOXECO LABS is seeking investment and strategic commercial partners for registration and marketing of five completed formulations. Three products have successful field-trial evidence; two feed additives are laboratory-tested, with controlled animal field trials next.

What the portfolio addresses

Product	Purpose and completed evidence
EIR Biostimulant	Botanical formulation for plant vitality and crop health. Field-tested; stability-tested.
EIR PESTOX	Contact insecticide and acaricide with sustained formic acid release. Field-tested; stability-tested.
EIROLITTER	Sustained litter acidification for ammonia management. Field-tested; stability-tested.
EIR AVIBIOME	Protected feed ingredients for intestinal function, microbial balance and eggshell support. Laboratory-tested; animal outcomes await field trials.
EIR BOVIBIOME	Rumen-protected butyrate delivery for intestinal function and microbial balance. Laboratory-tested; animal outcomes await field trials.

The technical proposition

The portfolio applies formulation and delivery expertise to recurring farm needs: stable botanical dispersions, sustained formic acid or mineral-acid availability, and protected intestinal delivery. Commercial value is assessed through product-specific performance, handling and application economics.

Selected evidence

EIR PESTOX: 85.8% aphid control at 0.25% after three days, against 29.2% for flonicamid 0.015%; four replicates in the March 2022 pepper trial.

EIROLITTER: 1-5 ppm ammonia across the treated-house cycle, versus 44.2 ppm in the control at week six; one house per treatment.

EIR Biostimulant: pepper disease severity at 0.1% fell from 2.89 to 0.08 over 29 days.

These are study-specific observations. Full conditions and interpretation are set out in the product briefs and at nontoxeco.eco/science.html.

Capital, milestones and commercial execution

The intended use of investment

Registration: dossier preparation, local regulatory work and requirements for the chosen product and jurisdiction.

Commercial launch: production and quality arrangements, channel development, local positioning, marketing and customer adoption.

Feed additives: controlled animal trials are a separate, explicitly budgeted milestone.

A staged route to market

1. Define the entry plan. Select product, territory, intended use and channel; establish the costed dossier and launch plan. The existing EIR Biostimulant entry plan starts in Thailand, with ASEAN expansion to follow.

2. Deliver registration work. Organise technical records, complete local submissions and track the market-specific regulatory milestones.

3. Prepare the launch. Agree manufacturing, quality controls, commercial terms and distributor support.

4. Review commercial execution. Assess orders, channel performance and product economics before expanding.

Commercial structures and diligence

Structures can include company investment, financing for a defined product and territory, licensed manufacturing or distribution. Agreements define rights, responsibilities and revenue arrangements. NONTOXECO retains ownership of its technologies and formulation know-how.

Diligence connects the formulation and trial records with registration requirements, manufacturing cost, application rate, channel margins and working capital. Capital requirement, valuation and timing are agreed from the selected scope; this public brief does not state a funding target or guaranteed launch date.

The people responsible

Ido Eco Ofek, Founder & Chief Scientist: more than 25 years in formulation research, chemistry, microbiology, agronomy and animal science.

Guy Shafir, CEO: more than 20 years in financial services, risk management and international business; leads strategy and commercialisation.

Start a focused discussion

eco@nontoxeco.eco | +66 61 296 2109

nontoxeco.eco/investors.html

NONTOXECO LABS LLC, Wyoming, USA. Teams in Bangkok, Jerusalem and Manila.

Public company overview, 18 October 2026. Detailed records are available under a mutual NDA. This information is not an offer of securities.